GlassScriptPhysician profile
Chanel J Wilkinson
NPI 1932104916
$2,539.00
in general payments reported to CMS, 2019-2025
22 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $923 · 2022: $78.85 · 2023: $606 · 2024: $510 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,537.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $589.92 | 2021-2024 | |
| Novo Nordisk INC | $354.40 | 2021-2023 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $340.73 | 2021-2025 | Kisunla, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $212.24 | 2024-2025 | Farxiga, Breztri |
| Amgen INC. | $129.82 | 2021 | |
| Kaleo, INC. | $129.43 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $107.61 | 2023 | Rexulti |
| Dexcom, INC. | $100.55 | 2023-2025 | Dexcom G6 Transmitter |
| Idorsia Pharmaceuticals US INC | $89.32 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $81.09 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.33 | 2021 | |
| Phathom Pharmaceuticals, INC. | $72.12 | 2025 | Voquezna |
| Amarin Pharma, INC. | $65.61 | 2021-2022 | |
| Glaxosmithkline, LLC. | $40.61 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Theratechnologies INC. | $27.62 | 2025 | Egrifta, Trogarzo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $25.09 | 2021 | |
| Abbott Laboratories | $22.05 | 2024 | Eterna |
| Novartis Pharmaceuticals Corporation | $18.48 | 2024 | |
| Exact Sciences Corporation | $16.78 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $14.26 | 2021 | |
| Edwards Lifesciences Corporation | $13.38 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chanel Wilkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.